Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sorrento Announces Drilling Contract & Receives Permit to Drill Bottom Brook Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News MaxCyte Inc MXCT

Healthcare Biotechnology
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell... see more

Current News (NDAQ:MXCT)

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire 3 days ago

MaxCyte Announces Planned CFO Transition in 2026

GlobeNewswire November 12, 2025

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

GlobeNewswire November 12, 2025

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

GlobeNewswire November 5, 2025

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

GlobeNewswire October 8, 2025

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

GlobeNewswire October 6, 2025

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

GlobeNewswire September 22, 2025

MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

GlobeNewswire August 6, 2025

MaxCyte Signs Platform License Agreement with Adicet Bio

GlobeNewswire August 4, 2025
View More News ››

Opinion & Analysis (NDAQ:MXCT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MXCT)

MAXCYTE: A PIONEER IN THE CELL THERAPY MARKET

  $MXCT Excited to share an article about MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering-focused...
AviseAnalytics - April 17, 2023
View more Bullboard ››

Atlas Salt Inc.

Atlas Salt Inc.

Atlas Salt Inc. engages in the evaluation, exploration and development of mineral properties in Newfoundland and Labrador ...
View More »

Podcasts